ClinicalTrials.gg
CompletedNCT04635423Updated Jun 11, 2026Results posted

Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064)

A Phase 3 interventional study of V503 and Placebo in Warts, Genital and Neoplasms, Anal, sponsored by Merck Sharp & Dohme LLC. Completed at 22 sites in Japan. Open to male participants aged 16 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,059
Allocation
Randomized
Ages
16 Years to 26 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata — 2 open to participants now, 4 under way, 3 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Condylomata Acuminata.

Enrollment
7th of 10
1,059 · median 1,206
Started
2020
with 1 other
Phase 3
9 of 10
1 open now
Registered
6th of 10
by date
Lead sponsor
6 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata, this one is the 7th largest by enrollment, is one of 2 that started in 2020, is one of 9 in phase 3, and was the 6th registered.

Condylomata Acuminata

116 studies on the registry are indexed under Condylomata Acuminata; 11 are open to participants now.

Browse Condylomata Acuminata studies →

Open to participants now

2 of the 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Condylomata Acuminata studies recruiting now, 1 sets no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 16 Years to 26 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata, or all of them as a file.
02

Study summary

The purposes of this phase 3, double-blind, placebo-controlled clinical study are to evaluate the efficacy of V503 in preventing human papillomavirus (HPV)-related anogenital persistent infection, and to evaluate the safety/tolerability of V503, in Japanese males who are 16 to 26 years of age. It is hypothesized that administration of a 3-dose regimen of V503 reduces the combined incidence of HPV 6/11/16/18-related anogenital persistent infection, as well as the combined incidence of HPV 31/33/45/52/58-related anogenital persistent infection, compared with placebo.

The study includes a Base Study to assess efficacy and safety of V503, and an Extension Study. Participants who received placebo in the Base Study will be eligible to receive V503 vaccine on Day 1, Month 2, and Month 6 of the Extension Study. Participants who received less than 3 doses of V503 in the Base Study will be offered the opportunity to complete the 3-dose regimen in the Extension Study.

03

Conditions studied

  • Warts, Genital
  • Neoplasms, Anal
04

Who can participate

Ages eligible
16 Years to 26 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is a Japanese male 16 to 26 years of age
  • Has no more than 5 lifetime sexual partners

Exclusion criteria

Exclusion Criteria:

  • Has a history of known prior vaccination with an HPV vaccine or plans to receive one outside the study
  • Has a history of external genital warts
  • Has a history of severe allergic reaction that required medical intervention
  • Has received immune globulin or blood-derived products in the past 3 months or plan to receive any before Month 7 of the study
  • Has a history of splenectomy, is currently , or has been diagnosed with immunodeficiency, (HIV), lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other condition
  • Has received immunosuppressive therapy in the past year, excluding inhaled, nasal, or topical and certain regimens of systemic corticosteroids
  • Has a known thrombocytopenia or coagulation disorder that would contraindicate intramuscular injections
  • Has ongoing alcohol or drug abuse within the past 12 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,059 participants (actual)

Study arms

  • Experimental
    V503

    In the base study, participants receive an intramuscular (IM) injection of V503 at Day 1, Month 2, and Month 6.

    Biological: V503

  • Placebo comparator
    Placebo

    In the base study, participants receive an IM injection of placebo at Day 1, Month 2, and Month 6.

    Other: Placebo

  • Experimental
    V503 → Open Label V503 Extension Study

    Participants from V503 arm of the base study who do not complete the 3-dose series receive 1 or 2 doses of V503, on Day 1, or Day 1 and Month 4 of the open label extension study.

    Biological: V503

  • Experimental
    Placebo → Open Label V503 Extension Study

    Participants from the placebo arm of the base study receive 3 doses of V503 on Day 1, Month 2 and Month 6 of the open label extension study.

    Biological: V503

Interventions

  • BiologicalV503

    9-valent vaccine, HPV 6/11/16/18/31/33/45/52/58, L1 virus-like particle (VLP) 30/40/60/40/20/20/20/20/20 mcg per dose.

    Also known as: 9vHPV vaccine, SILGARD®9, GARDASIL™9

  • OtherPlacebo

    0.9% sodium chloride (NaCL)

06

What researchers measure

Primary outcomes

  1. Base Study: Combined Incidence of Human Papillomavirus (HPV) 6/11/16/18-related Anogenital Persistent Infection

    Combined incidence of HPV type(s) 6/11/16/18-related anogenital persistent infection was defined to have occurred in a participant; 1) who is polymerase chain reaction (PCR) positive to at least one applicable HPV type(s) in 2 consecutive anogenital or biopsy samples from at least 2 consecutive visits 6 months (±1 month visit) or longer apart, or 2) who has a pathology diagnosis of condyloma, penile/perineal/perianal intraepithelial neoplasia, or penile, perineal or perianal cancer and PCR detection of at least one applicable HPV type(s) in an adjacent section and PCR positive for the same HPV type at a separate adjacent visit with regardless of visit interval, prior to or following the biopsy showing HPV disease. Incidence was defined as the number of cases per 100 person-years of follow-up in both V503 and placebo arms. Per protocol, cases per 100 person-years is reported for applicable HPV type eligible participants with data available in the per-protocol efficacy population (PPE).

    Time frame: Up to approximately 36 Months

  2. Base Study: Percentage of Participants With Solicited Injection-site Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The participant recorded the presence of any vaccination report card (VRC)-prompted injection-site AEs that occurred in the 5 days after any vaccination. The percentage of participants with an injection-site AE prompted on the VRC (redness/erythema, tenderness/pain, and swelling) is reported here for all randomized participants in the All Participants as Treated (APaT) population.

    Time frame: Up to 5 days after any vaccination

  3. Base Study: Percentage of Participants With ≥1 Systemic AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least 1 systemic AE is reported here for all randomized participants in the All Participants as Treated (APaT) population.

    Time frame: Up to 15 days after any vaccination

  4. Base Study: Percentage of Participants With ≥1 Serious Adverse Events (SAEs)

    An SAE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention, that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, results in persistent/significant disability/incapacity, is a congenital birth defect, or is another important medical event. The percentage of participants who experienced at least 1 SAE is reported here for all randomized participants in the All Participants as Treated (APaT) population.

    Time frame: Up to approximately 37 months

  5. Base Study: Number of Participants With Elevated Oral Body Temperature

    Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded using the vaccination report card (VRC). Per protocol, fever was defined as an oral temperature of ≥99.5°F(37.5°C). The number of participants who had at least 1 oral body temperature reading that was, \<99.5°F (\<37.5ºC), ≥99.5°F (≥37.5ºC) and \<100.4°F (38.0°C), or ≥100.4°F (38.0°C) and \<101.3°F(38.5°C), or ≥101.3°F(38.5°C) is reported here for all randomized participants in the APaT population with temperature data available.

    Time frame: Up to 5 days after any vaccination

Secondary outcomes

  1. Base Study: Combined Incidence of HPV 31/33/45/52/58-related Anogenital Persistent Infection

    Combined incidence of HPV type(s) 31/33/45/52/58-related anogenital persistent infection was defined to have occurred in a participant; 1) who is polymerase chain reaction (PCR) positive to at least 1 applicable HPV type(s) in 2 consecutive anogenital or biopsy samples from at least 2 consecutive visits 6 months (±1 month visit) or longer apart, or 2) who has a pathology diagnosis of condyloma, penile/perineal/perianal intraepithelial neoplasia, or penile, perineal or perianal cancer and PCR detection of at least 1 applicable HPV type in an adjacent section and PCR positive for the same HPV type at a separate adjacent visit with regardless of visit interval, prior to or following the biopsy showing HPV disease. Incidence was defined as the number of cases per 100 person-years of follow-up in both V503 and placebo arms. Per protocol, cases per 100 person-years is reported for applicable HPV type(s) eligible participants with data available in the per-protocol efficacy population (PPE).

    Time frame: Up to approximately 36 Months

  2. Base Study: Geometric Mean Titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58 - All Randomized Participants

    Antibodies to the HPV types 6/11/16/18/31/33/45/52/58 contained in V503 were measured using a competitive Luminex immunoassay (cLIA). Per protocol, antibody titers were expressed as milli Merck units/milliliter (mMU/mL). Geometric Mean Titers (GMTs) is reported for both V503 and Placebo for all randomized participants of the per-protocol immunogenicity population (PPI).

    Time frame: Month 7

  3. Base Study: Geometric Mean Titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58 - Heterosexual Males (HM) Participant Subgroup

    Antibodies to the HPV types 6/11/16/18/31/33/45/52/58 contained in V503 were measured using a competitive Luminex immunoassay (cLIA). Per protocol, antibody titers were expressed as milli Merck units/milliliter (mMU/mL). Geometric Mean Titers (GMTs) is reported for both V503 and Placebo for the heterosexual males (HM) subgroup of the per-protocol immunogenicity population (PPI).

    Time frame: Month 7

  4. Base Study: Geometric Mean Titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58 - Males Who Have Sex With Males (MSM) Participant Subgroup

    Antibodies to the HPV types 6/11/16/18/31/33/45/52/58 contained in V503 were measured using a competitive Luminex immunoassay (cLIA). Per protocol, antibody titers were expressed as milli Merck units/milliliter (mMU/mL). Geometric Mean Titers (GMTs) is reported for both V503 and Placebo for the males who have sex with males (MSM) subgroup of the per-protocol immunogenicity population (PPI).

    Time frame: Month 7

  5. Base Study: Percentage of Participants With Seroconversion to HPV 6/11/16/18/31/33/45/52/58 - All Randomized Participants

    Percentage of seroconversion to each of HPV 6/11/16/18/31/33/45/52/58 at Month 7 based on competitive Luminex immunoassay (cLIA) from participant serum samples. Seroconversion is defined as changing a participant's serostatus from seronegative at Day 1 to seropositive at 1 month post last dose Month 7. A participant with anti-HPV cLIA titer at or above the serostatus cutoff values of the cLIA for a given HPV type is considered seropositive for that HPV type. The serostatus cutoffs (milli Merck units/milliliter (mMU/mL)) for HPV types were as follows: HPV Type 6: ≥65, HPV Type 11: ≥37; HPV Type 16: ≥79, HPV Type 18: ≥85, HPV Type 31: ≥46, HPV Type 33: ≥26, HPV Type 45: ≥21, HPV Type 52: ≥30, and HPV Type 58: ≥31. The percentage of participants with seroconversion is reported for both V503 and Placebo for all randomized participants of the per-protocol immunogenicity population (PPI).

    Time frame: Month 7

  6. Base Study: Percentage of Participants With Seroconversion to HPV 6/11/16/18/31/33/45/52/58 - Heterosexual Males (HM) Participant Subgroup

    Percentage of seroconversion to each of HPV 6/11/16/18/31/33/45/52/58 at Month 7 based on competitive Luminex immunoassay (cLIA) from participant serum samples. Seroconversion is defined as changing a participant's serostatus from seronegative at Day 1 to seropositive at 1 month post last dose Month 7. A participant with anti-HPV cLIA titer at or above the serostatus cutoff values of the cLIA for a given HPV type is considered seropositive for that HPV type. The serostatus cutoffs (milli Merck units/milliliter (mMU/mL)) for HPV types were as follows: HPV Type 6: ≥65, HPV Type 11: ≥37; HPV Type 16: ≥79, HPV Type 18: ≥85, HPV Type 31: ≥46, HPV Type 33: ≥26, HPV Type 45: ≥21, HPV Type 52: ≥30, and HPV Type 58: ≥31. The percentage of participants with seroconversion is reported for both V503 and Placebo for the heterosexual males (HM) subgroup of the per-protocol immunogenicity population (PPI).

    Time frame: Month 7

  7. Base Study: Percentage of Participants With Seroconversion to HPV 6/11/16/18/31/33/45/52/58 - Males Who Have Sex With Males (MSM) Participant Subgroup

    Percentage of seroconversion to each of HPV 6/11/16/18/31/33/45/52/58 at Month 7 based on competitive Luminex immunoassay (cLIA) from participant serum samples. Seroconversion is defined as changing a participant's serostatus from seronegative at Day 1 to seropositive at 1 month post last dose Month 7. A participant with anti-HPV cLIA titer at or above the serostatus cutoff values of the cLIA for a given HPV type is considered seropositive for that HPV type. The serostatus cutoffs (milli Merck units/milliliter (mMU/mL)) for HPV types were as follows: HPV Type 6: ≥65, HPV Type 11: ≥37; HPV Type 16: ≥79, HPV Type 18: ≥85, HPV Type 31: ≥46, HPV Type 33: ≥26, HPV Type 45: ≥21, HPV Type 52: ≥30, and HPV Type 58: ≥31. The percentage of participants with seroconversion is reported for both V503 and Placebo for the males who have sex with males (MSM) subgroup of the per-protocol immunogenicity population (PPI).

    Time frame: Month 7

07

Results

Posted Jan 13, 2025

Participant flow

Base Study
Participant flow — Base Study
MilestoneV503PlaceboV503 → Open Label V503 Extension StudyPlacebo → Open Label V503 Extension Study
Started52953000
Vaccination 1: day 152953000
Vaccination 2: month 252351800
Vaccination 3: month 651450800
Completed46447200
Not completed655800
Withdrew: Withdrawal by subject574200
Withdrew: Lost to follow-up81600
Extension Study
Participant flow — Extension Study
MilestoneV503PlaceboV503 → Open Label V503 Extension StudyPlacebo → Open Label V503 Extension Study
Started002381
Completed002367
Not completed00014
Withdrew: Lost to follow-up0003
Withdrew: Withdrawal by subject00010
Withdrew: Physician decision0001

Outcome measures

PrimaryBase Study: Combined Incidence of Human Papillomavirus (HPV) 6/11/16/18-related Anogenital Persistent Infection

Combined incidence of HPV type(s) 6/11/16/18-related anogenital persistent infection was defined to have occurred in a participant; 1) who is polymerase chain reaction (PCR) positive to at least one applicable HPV type(s) in 2 consecutive anogenital or biopsy samples from at least 2 consecutive visits 6 months (±1 month visit) or longer apart, or 2) who has a pathology diagnosis of condyloma, penile/perineal/perianal intraepithelial neoplasia, or penile, perineal or perianal cancer and PCR detection of at least one applicable HPV type(s) in an adjacent section and PCR positive for the same HPV type at a separate adjacent visit with regardless of visit interval, prior to or following the biopsy showing HPV disease. Incidence was defined as the number of cases per 100 person-years of follow-up in both V503 and placebo arms. Per protocol, cases per 100 person-years is reported for applicable HPV type eligible participants with data available in the per-protocol efficacy population (PPE).

Time frame:
Up to approximately 36 Months
Reported as:
Number · Cases per 100 Person-years
Base Study: Combined Incidence of Human Papillomavirus (HPV) 6/11/16/18-related Anogenital Persistent Infection
Cases per 100 Person-yearsV503Placebo
Base Study: Combined Incidence of Human Papillomavirus (HPV) 6/11/16/18-related Anogenital Persistent Infection0.22.2
Statistical analysis
  • V503 vs Placebo · Exact Binomial Method Chan and Bohidar · p = <0.001 (one-sided p-value based on exact binomial method proposed by Chan and Bohidar) · Observed efficacy (%): 89.3 · 95% CI 55.4 to 98.2The statistical criterion for success requires that the lower bound of the 2-sided 95% confidence interval (CI) for vaccine efficacy (VE) against the primary efficacy endpoint is greater than 0%.
PrimaryBase Study: Percentage of Participants With Solicited Injection-site Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The participant recorded the presence of any vaccination report card (VRC)-prompted injection-site AEs that occurred in the 5 days after any vaccination. The percentage of participants with an injection-site AE prompted on the VRC (redness/erythema, tenderness/pain, and swelling) is reported here for all randomized participants in the All Participants as Treated (APaT) population.

Time frame:
Up to 5 days after any vaccination
Reported as:
Number · Percentage of Participants
Base Study: Percentage of Participants With Solicited Injection-site Adverse Events (AEs)
Percentage of ParticipantsV503Placebo
Base Study: Percentage of Participants With Solicited Injection-site Adverse Events (AEs)69.829.6
Statistical analysis
  • V503 vs Placebo · Miettinen & Nurminen method · Difference in percentages: 40.1 · 95% CI 34.5 to 45.5Difference in percentages calculated as % V503 minus % Placebo.
PrimaryBase Study: Percentage of Participants With ≥1 Systemic AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least 1 systemic AE is reported here for all randomized participants in the All Participants as Treated (APaT) population.

Time frame:
Up to 15 days after any vaccination
Reported as:
Number · Percentage of Participants
Base Study: Percentage of Participants With ≥1 Systemic AE
Percentage of ParticipantsV503Placebo
Base Study: Percentage of Participants With ≥1 Systemic AE20.219.8
Statistical analysis
  • V503 vs Placebo · Miettinen & Nurminen method · Difference in percentage: 0.4 · 95% CI -4.4 to 5.2Difference in percentages calculated as % V503 minus % Placebo.
PrimaryBase Study: Percentage of Participants With ≥1 Serious Adverse Events (SAEs)

An SAE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention, that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, results in persistent/significant disability/incapacity, is a congenital birth defect, or is another important medical event. The percentage of participants who experienced at least 1 SAE is reported here for all randomized participants in the All Participants as Treated (APaT) population.

Time frame:
Up to approximately 37 months
Reported as:
Number · Percentage of Participants
Base Study: Percentage of Participants With ≥1 Serious Adverse Events (SAEs)
Percentage of ParticipantsV503Placebo
Base Study: Percentage of Participants With ≥1 Serious Adverse Events (SAEs)1.30.9
PrimaryBase Study: Number of Participants With Elevated Oral Body Temperature

Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded using the vaccination report card (VRC). Per protocol, fever was defined as an oral temperature of ≥99.5°F(37.5°C). The number of participants who had at least 1 oral body temperature reading that was, \<99.5°F (\<37.5ºC), ≥99.5°F (≥37.5ºC) and \<100.4°F (38.0°C), or ≥100.4°F (38.0°C) and \<101.3°F(38.5°C), or ≥101.3°F(38.5°C) is reported here for all randomized participants in the APaT population with temperature data available.

Time frame:
Up to 5 days after any vaccination
Reported as:
Count of participants · Participants
Base Study: Number of Participants With Elevated Oral Body Temperature
ParticipantsV503Placebo
<99.5°F (37.5°C)502496
≥99.5°F (≥37.5ºC) and <100.4°F (38.0°C)1922
≥100.4°F (38.0°C) and <101.3°F(38.5°C)11
≥101.3°F(38.5°C)57
SecondaryBase Study: Combined Incidence of HPV 31/33/45/52/58-related Anogenital Persistent Infection

Combined incidence of HPV type(s) 31/33/45/52/58-related anogenital persistent infection was defined to have occurred in a participant; 1) who is polymerase chain reaction (PCR) positive to at least 1 applicable HPV type(s) in 2 consecutive anogenital or biopsy samples from at least 2 consecutive visits 6 months (±1 month visit) or longer apart, or 2) who has a pathology diagnosis of condyloma, penile/perineal/perianal intraepithelial neoplasia, or penile, perineal or perianal cancer and PCR detection of at least 1 applicable HPV type in an adjacent section and PCR positive for the same HPV type at a separate adjacent visit with regardless of visit interval, prior to or following the biopsy showing HPV disease. Incidence was defined as the number of cases per 100 person-years of follow-up in both V503 and placebo arms. Per protocol, cases per 100 person-years is reported for applicable HPV type(s) eligible participants with data available in the per-protocol efficacy population (PPE).

Time frame:
Up to approximately 36 Months
Reported as:
Number · cases per 100 Person-years
Base Study: Combined Incidence of HPV 31/33/45/52/58-related Anogenital Persistent Infection
cases per 100 Person-yearsV503Placebo
Base Study: Combined Incidence of HPV 31/33/45/52/58-related Anogenital Persistent Infection0.71.9
Statistical analysis
  • V503 vs Placebo · Exact Binomial Method Chan and Bohidar · p = 0.023 (one-sided p-value based on exact binomial method proposed by Chan and Bohidar) · Observed efficacy (%): 63.5 · 95% CI 2.7 to 86.0The statistical criterion for success requires that the lower bound of the 2-sided 95% confidence interval (CI) for vaccine efficacy (VE) against the primary efficacy endpoint is greater than 0%.
SecondaryBase Study: Geometric Mean Titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58 - All Randomized Participants

Antibodies to the HPV types 6/11/16/18/31/33/45/52/58 contained in V503 were measured using a competitive Luminex immunoassay (cLIA). Per protocol, antibody titers were expressed as milli Merck units/milliliter (mMU/mL). Geometric Mean Titers (GMTs) is reported for both V503 and Placebo for all randomized participants of the per-protocol immunogenicity population (PPI).

Time frame:
Month 7
Reported as:
Geometric mean · mMU/mL
Base Study: Geometric Mean Titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58 - All Randomized Participants
mMU/mLV503Placebo
Anti-HPV 6927.3 (850.2 to 1011.3)21.1 (NA to 22.5)
Anti-HPV 11716.5 (654.4 to 784.5)NA (NA to NA)
Anti-HPV 163491.6 (3196.5 to 3814.0)NA (NA to NA)
Anti-HPV 18998.0 (904.3 to 1101.4)45.5 (43.4 to 47.7)
HPV-31832.1 (753.3 to 919.2)15.4 (14.3 to 16.5)
HPV-33489.8 (448.6 to 534.7)12.7 (11.9 to 13.4)
Anti-HPV 45326.6 (293.7 to 363.2)8.5 (NA to 9.0)
Anti-HPV 52390.5 (356.3 to 428.0)10.1 (9.5 to 10.8)
Anti-HPV 58588.3 (537.7 to 643.6)NA (NA to NA)
SecondaryBase Study: Geometric Mean Titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58 - Heterosexual Males (HM) Participant Subgroup

Antibodies to the HPV types 6/11/16/18/31/33/45/52/58 contained in V503 were measured using a competitive Luminex immunoassay (cLIA). Per protocol, antibody titers were expressed as milli Merck units/milliliter (mMU/mL). Geometric Mean Titers (GMTs) is reported for both V503 and Placebo for the heterosexual males (HM) subgroup of the per-protocol immunogenicity population (PPI).

Time frame:
Month 7
Reported as:
Geometric mean · mMU/mL
Base Study: Geometric Mean Titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58 - Heterosexual Males (HM) Participant Subgroup
mMU/mLV503Placebo
Anti-HPV 6950.2 (866.8 to 1041.6)21.0 (NA to 22.6)
Anti-HPV 11730.6 (664.4 to 803.4)NA (NA to NA)
Anti-HPV 163608.3 (3288.6 to 3959.0)NA (NA to NA)
Anti-HPV 181044.7 (942.7 to 1157.7)45.1 (42.9 to 47.3)
Anti-HPV 31867.8 (780.7 to 964.7)15.1 (14.0 to 16.3)
Anti-HPV 33495.4 (451.9 to 543.1)12.6 (11.8 to 13.4)
Anti-HPV 45333.8 (298.4 to 373.5)8.4 (NA to 9.0)
Ant-HPV 52408.7 (372.1 to 448.9)10.0 (9.3 to 10.7)
Anti-HPV 58609.1 (554.2 to 669.4)NA (NA to NA)
SecondaryBase Study: Geometric Mean Titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58 - Males Who Have Sex With Males (MSM) Participant Subgroup

Antibodies to the HPV types 6/11/16/18/31/33/45/52/58 contained in V503 were measured using a competitive Luminex immunoassay (cLIA). Per protocol, antibody titers were expressed as milli Merck units/milliliter (mMU/mL). Geometric Mean Titers (GMTs) is reported for both V503 and Placebo for the males who have sex with males (MSM) subgroup of the per-protocol immunogenicity population (PPI).

Time frame:
Month 7
Reported as:
Geometric mean · mMU/mL
Base Study: Geometric Mean Titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58 - Males Who Have Sex With Males (MSM) Participant Subgroup
mMU/mLV503Placebo
Anti-HPV 6740.2 (569.2 to 962.6)21.5 (NA to 27.5)
Anti-HPV 11598.8 (438.7 to 817.3)NA (NA to NA)
Anti-HPV 162599.5 (1957.4 to 3452.4)NA (NA to NA)
Anti-HPV 18677.4 (487.6 to 941.0)49.7 (42.1 to 58.6)
Anti-HPV 31593.2 (446.0 to 789.0)17.7 (14.1 to 22.2)
Anti-HPV 33443.6 (327.9 to 600.1)13.5 (11.5 to 16.0)
Anti-HPV 45266.6 (190.1 to 373.8)9.1 (NA to 11.1)
Anti-HPV 52262.9 (186.7 to 370.2)11.3 (9.0 to 14.2)
Anti-HPV 58437.7 (327.8 to 584.5)NA (NA to 8.4)
SecondaryBase Study: Percentage of Participants With Seroconversion to HPV 6/11/16/18/31/33/45/52/58 - All Randomized Participants

Percentage of seroconversion to each of HPV 6/11/16/18/31/33/45/52/58 at Month 7 based on competitive Luminex immunoassay (cLIA) from participant serum samples. Seroconversion is defined as changing a participant's serostatus from seronegative at Day 1 to seropositive at 1 month post last dose Month 7. A participant with anti-HPV cLIA titer at or above the serostatus cutoff values of the cLIA for a given HPV type is considered seropositive for that HPV type. The serostatus cutoffs (milli Merck units/milliliter (mMU/mL)) for HPV types were as follows: HPV Type 6: ≥65, HPV Type 11: ≥37; HPV Type 16: ≥79, HPV Type 18: ≥85, HPV Type 31: ≥46, HPV Type 33: ≥26, HPV Type 45: ≥21, HPV Type 52: ≥30, and HPV Type 58: ≥31. The percentage of participants with seroconversion is reported for both V503 and Placebo for all randomized participants of the per-protocol immunogenicity population (PPI).

Time frame:
Month 7
Reported as:
Number · Percentage of Participants
Base Study: Percentage of Participants With Seroconversion to HPV 6/11/16/18/31/33/45/52/58 - All Randomized Participants
Percentage of ParticipantsV503Placebo
Anti-HPV 6 cLIA ≥65 mMU/mL99.7 (98.6 to 100.0)3.5 (1.9 to 6.0)
Anti-HPV 11 cLIA ≥37 mMU/mL99.7 (98.6 to 100.0)4.1 (2.3 to 6.7)
Anti-HPV 16 cLIA ≥79 mMU/mL99.6 (98.4 to 99.9)4.3 (2.6 to 6.6)
Anti-HPV 18 cLIA ≥85 mMU/mL99.3 (97.9 to 99.9)8.3 (5.8 to 11.4)
Anti-HPV 31 cLIA ≥46 mMU/mL98.9 (97.3 to 99.6)5.6 (3.6 to 8.2)
Anti-HPV 33 cLIA ≥26 mMU/mL99.8 (98.8 to 100.0)11.1 (8.3 to 14.4)
Anti-HPV 45 cLIA ≥21 mMU/mL98.9 (97.4 to 99.6)9.0 (6.5 to 12.1)
Anti-HPV 52 cLIA ≥30 mMU/mL98.9 (97.4 to 99.6)4.2 (2.5 to 6.5)
Anti-HPV 58 cLIA ≥31 mMU/mL99.3 (98.1 to 99.9)1.5 (0.6 to 3.1)
SecondaryBase Study: Percentage of Participants With Seroconversion to HPV 6/11/16/18/31/33/45/52/58 - Heterosexual Males (HM) Participant Subgroup

Percentage of seroconversion to each of HPV 6/11/16/18/31/33/45/52/58 at Month 7 based on competitive Luminex immunoassay (cLIA) from participant serum samples. Seroconversion is defined as changing a participant's serostatus from seronegative at Day 1 to seropositive at 1 month post last dose Month 7. A participant with anti-HPV cLIA titer at or above the serostatus cutoff values of the cLIA for a given HPV type is considered seropositive for that HPV type. The serostatus cutoffs (milli Merck units/milliliter (mMU/mL)) for HPV types were as follows: HPV Type 6: ≥65, HPV Type 11: ≥37; HPV Type 16: ≥79, HPV Type 18: ≥85, HPV Type 31: ≥46, HPV Type 33: ≥26, HPV Type 45: ≥21, HPV Type 52: ≥30, and HPV Type 58: ≥31. The percentage of participants with seroconversion is reported for both V503 and Placebo for the heterosexual males (HM) subgroup of the per-protocol immunogenicity population (PPI).

Time frame:
Month 7
Reported as:
Number · Percentage of Participants
Base Study: Percentage of Participants With Seroconversion to HPV 6/11/16/18/31/33/45/52/58 - Heterosexual Males (HM) Participant Subgroup
Percentage of ParticipantsV503Placebo
Anti-HPV 6 cLIA ≥65 mMU/mL99.7 (98.5 to 100.0)3.5 (1.8 to 6.1)
Anti-HPV 11 cLIA ≥37 mMU/mL99.7 (98.5 to 100.0)4.4 (2.5 to 7.2)
Anti-HPV 16 cLIA ≥79 mMU/mL99.5 (98.2 to 99.9)3.7 (2.1 to 6.0)
Anti-HPV 18 cLIA ≥85 mMU/mL99.5 (98.1 to 99.9)7.6 (5.1 to 10.8)
Anti-HPV 31 cLIA ≥46 mMU/mL99.0 (97.4 to 99.7)5.2 (3.2 to 7.9)
Anti-HPV 33 cLIA ≥26 mMU/mL99.8 (98.6 to 100.0)11.4 (8.4 to 14.9)
Anti-HPV 45 cLIA ≥21 mMU/mL98.7 (97.1 to 99.6)8.5 (5.9 to 11.7)
Anti-HPV 52 cLIA ≥30 mMU/mL99.2 (97.8 to 99.8)3.8 (2.2 to 6.3)
Anti-HPV 58 cLIA ≥31 mMU/mL99.3 (97.9 to 99.8)1.7 (0.7 to 3.4)
SecondaryBase Study: Percentage of Participants With Seroconversion to HPV 6/11/16/18/31/33/45/52/58 - Males Who Have Sex With Males (MSM) Participant Subgroup

Percentage of seroconversion to each of HPV 6/11/16/18/31/33/45/52/58 at Month 7 based on competitive Luminex immunoassay (cLIA) from participant serum samples. Seroconversion is defined as changing a participant's serostatus from seronegative at Day 1 to seropositive at 1 month post last dose Month 7. A participant with anti-HPV cLIA titer at or above the serostatus cutoff values of the cLIA for a given HPV type is considered seropositive for that HPV type. The serostatus cutoffs (milli Merck units/milliliter (mMU/mL)) for HPV types were as follows: HPV Type 6: ≥65, HPV Type 11: ≥37; HPV Type 16: ≥79, HPV Type 18: ≥85, HPV Type 31: ≥46, HPV Type 33: ≥26, HPV Type 45: ≥21, HPV Type 52: ≥30, and HPV Type 58: ≥31. The percentage of participants with seroconversion is reported for both V503 and Placebo for the males who have sex with males (MSM) subgroup of the per-protocol immunogenicity population (PPI).

Time frame:
Month 7
Reported as:
Number · Percentage of Participants
Base Study: Percentage of Participants With Seroconversion to HPV 6/11/16/18/31/33/45/52/58 - Males Who Have Sex With Males (MSM) Participant Subgroup
Percentage of ParticipantsV503Placebo
Anti-HPV 6 cLIA ≥65 mMU/mL100.0 (91.0 to 100.0)3.6 (0.1 to 18.3)
Anti-HPV 11 cLIA ≥37 mMU/mL100.0 (91.0 to 100.0)0.0 (0.0 to 12.3)
Anti-HPV 16 cLIA ≥79 mMU/mL100.0 (92.1 to 100.0)9.5 (2.7 to 22.6)
Anti-HPV 18 cLIA ≥85 mMU/mL97.7 (88.0 to 99.9)14.3 (5.4 to 28.5)
Anti-HPV 31 cLIA ≥46 mMU/mL97.9 (88.9 to 99.9)8.9 (2.5 to 21.2)
Anti-HPV 33 cLIA ≥26 mMU/mL100.0 (92.5 to 100.0)8.7 (2.4 to 20.8)
Anti-HPV 45 cLIA ≥21 mMU/mL100.0 (91.8 to 100.0)13.3 (5.1 to 26.8)
Anti-HPV 52 cLIA ≥30 mMU/mL95.6 (84.9 to 99.5)7.0 (1.5 to 19.1)
Anti-HPV 58 cLIA ≥31 mMU/mL100.0 (92.6 to 100.0)0.0 (0.0 to 8.2)

Adverse events

Collected over Up to approximately 55 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Base Study: V5030/529 (0%)7/529 (1.3%)374/529 (70.7%)
Base Study: Placebo0/530 (0%)5/530 (0.9%)183/530 (34.5%)
Base Study: V503 → Open Label V503 Extension Study0/2 (0%)0/2 (0%)0/2 (0%)
Base Study: Placebo → Open Label V503 Extension Study0/381 (0%)2/381 (0.5%)0/381 (0%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventBase Study: V503Base Study: PlaceboBase Study: V503 → Open Label V503 Extension StudyBase Study: Placebo → Open Label V503 Extension Study
Gastroenteritis viralInfections and infestations0/5290/5300/21/381
Ankle fractureInjury, poisoning and procedural complications0/5290/5300/21/381
Colitis ulcerativeGastrointestinal disorders1/5290/5300/20/381
AppendicitisInfections and infestations1/5291/5300/20/381
COVID-19Infections and infestations1/5291/5300/20/381
Campylobacter gastroenteritisInfections and infestations1/5290/5300/20/381
Chronic tonsillitisInfections and infestations1/5290/5300/20/381
Brain contusionInjury, poisoning and procedural complications1/5290/5300/20/381
PneumothoraxRespiratory, thoracic and mediastinal disorders1/5290/5300/20/381
PeritonitisInfections and infestations0/5291/5300/20/381
Most frequent other events
Most frequent other events
EventBase Study: V503Base Study: PlaceboBase Study: V503 → Open Label V503 Extension StudyBase Study: Placebo → Open Label V503 Extension Study
Injection site painGeneral disorders360/529122/5300/20/381
Injection site swellingGeneral disorders118/52940/5300/20/381
Injection site erythemaGeneral disorders104/52970/5300/20/381
PyrexiaGeneral disorders29/52933/5300/20/381

Baseline characteristics

Age, Continuous
Age, Continuous(Years)V503PlaceboTotal
Mean22.9 ± 2.122.8 ± 2.122.9 ± 2.1
Sex: Female, Male
Sex: Female, Male(Participants)V503PlaceboTotal
Female000
Male5295301059
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)V503PlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino5295301059
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)V503PlaceboTotal
American Indian or Alaska Native000
Asian5295301059
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Sexual Orientation Participant Subgroups
Sexual Orientation Participant Subgroups(Participants)V503PlaceboTotal
Heterosexual Males (HM)473474947
Males Who Have Sex With Males (MSM)5656112
08

Study locations

22 sites
  • Umeyama Clinic ( Site 6406)
    Takasaki, Gunma 370-0826, Japan
  • Association of Healthcare Corporation Koukankai Koukan Clinic ( Site 6424)
    Kawasaki, Kanagawa 210-0852, Japan
  • Ocean Clinic ( Site 6407)
    Yokohama, Kanagawa 231-8331, Japan
  • Kanno Clinic ( Site 6402)
    Sakai, Osaka 590-0024, Japan
  • P-One Clinic, Keikokai Medical Corp. ( Site 6419)
    Hachiōji, Tokyo 192-0071, Japan
  • Iwasa Clinic ( Site 6411)
    Osaka, 542-0073, Japan
  • Nomura Clinic Namba ( Site 6405)
    Osaka, 542-0076, Japan
  • Medical Corporation Seiwakai Hayakawa Clinic ( Site 6409)
    Osaka, 542-0086, Japan
  • Yamanaka Clinic ( Site 6410)
    Osaka, 553-0001, Japan
  • Doujin Memorial Medical Foundation, Meiwa Hospital ( Site 6404)
    Tokyo, 101-0041, Japan
  • Yuge Clinic ( Site 6421)
    Tokyo, 103-0014, Japan
  • Taisei Clinic ( Site 6403)
    Tokyo, 107-0052, Japan
  • Mildix Skin Clinic ( Site 6423)
    Tokyo, 120-0034, Japan
  • Sugisawa Dermatology Clinic ( Site 6422)
    Tokyo, 125-0041, Japan
  • Medical Corporation Sanshikai Toru Clinic ( Site 6401)
    Tokyo, 132-0011, Japan
  • Medical Corporation Mori to Umi Tokyo Tokyo Kamata Hospital ( Site 6418)
    Tokyo, 144-0051, Japan
  • Seiyukai Medical Corporation Itoh Skin Clinic ( Site 6416)
    Tokyo, 154-0024, Japan
  • Naoko Dermatology Clinic ( Site 6417)
    Tokyo, 158-0097, Japan
  • Medical Corporation Iseikai My City Clinic ( Site 6414)
    Tokyo, 160-0022, Japan
  • Shinjuku Higashiguchi Clinic ( Site 6415)
    Tokyo, 160-0022, Japan
  • Ogikuboekimae Clinic ( Site 6413)
    Tokyo, 167-0051, Japan
  • Kusunoki Clinic ( Site 6412)
    Tokyo, 175-0092, Japan
09

References and documents

Publications

  • Bergman H, Henschke N, Arevalo-Rodriguez I, Buckley BS, Crosbie EJ, Davies JC, Dwan K, Golder SP, Loke YK, Probyn K, Petkovic J, Villanueva G, Morrison J. Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. Cochrane Database Syst Rev. 2025 Nov 24;11(11):CD015364. doi: 10.1002/14651858.CD015364.pub2. PubMed 41276263 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Dec 2023, 37 months.

Results were first posted in Jan 2025, 1 year after primary completion.

Of 28 phase 3 interventional studies under Condylomata Acuminata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's 37 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2020
First posted
Nov 19, 2020
StartActual
Nov 30, 2020
Primary completionActual
Dec 31, 2023
CompletionActual
Jul 23, 2025
Results first posted
Jan 13, 2025
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04635423
Responsible party
Sponsor
First posted
Nov 19, 2020
Start date
Nov 30, 2020
Primary completion
Dec 31, 2023
Completion
Jul 23, 2025
Results posted
Jan 13, 2025
Last update
Jun 11, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion